Selpercatinib in Treatment of Advanced Medullary Thyroid Cancer: Effectiveness and Side Effects – A Case Report of 2 Patients during 60 Months of Therapy
Case Reports in Oncology · 2026-08-22 · 19 (1) · 1512-1523
DOI: 10.1159/cro/abzag009 ↗Abstract
Introduction: Medullary thyroid carcinoma (MTC) is a rare, but aggressive tumor that accounts for 4% of thyroid carcinomas. A mutation in the proto-oncogene RET has been shown to occur in ca. 70% of those neoplasia. Selpercatinib is a newly approved drug that specifically targets the RET-kinase and demonstrated a very high efficacy in reducing the tumor activity and in progression-free survival in patients with an advanced metastatic disease [1]. Case Presentation: In accordance with the approval of the FDA, we started a treatment with selpercatinib on 2 patients with advanced metastatic MTC with an established RET mutation. They received selpercatinib 160 mg bidaily, and we observed the patients for 60 months. We observed a very good metabolic and serological response to the treatment with a decrease in the tumor marker of 99.8% and 98.5% and stable imaging. Hypertension grade II, hypotension grade I, proteinuria grade I, hyperphosphatemia grade I, and hypocalcemia grade II were the low-grade side effects that we observed during these 60 months of therapy. Conclusion: Selpercatinib proved to be a good antineoplastic drug for patients with RET-mutated, advanced, and inoperable MTC.
EUVIMED